Patterns After Administration of MCFAs in Psoriasis and Psoriatic Arthritis
NCT ID: NCT03409211
Last Updated: 2020-12-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
22 participants
INTERVENTIONAL
2017-12-12
2019-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The patients and healthy controls will receive placebo or PEVCO for a total of 9 weeks (3 weeks for placebo, followed by 6 weeks for PEVCO). No topical or systemic medications will be used during this period.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pso
with or without PsA
PEVCO
All subjects will receive PEVCO for 6 more weeks.
Dietary Supplement Capsules without Coconut Oil
All subjects will receive placebo (PBO) for 3 weeks
Healthy Subjects
Without PsA
PEVCO
All subjects will receive PEVCO for 6 more weeks.
Dietary Supplement Capsules without Coconut Oil
All subjects will receive placebo (PBO) for 3 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PEVCO
All subjects will receive PEVCO for 6 more weeks.
Dietary Supplement Capsules without Coconut Oil
All subjects will receive placebo (PBO) for 3 weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Previous intolerance to PEVCO or related compounds
* Current (within 3 months of screening) treatment with DMARDs
* Current (within 3 months of screening) treatment with biologic therapies (including but limited to anti-TNF,anti-IL-17, anti-IL-12/23)
* Current antibiotic treatment (within 3 months of screening)
* current consumption of probiotics (within 3 months of screening)
* Severe hepatic impairment (eg, ac-sites and/or clinical signs of coagulopathy)
* Renal failure (eGFR ,30 or require dialysis) by history
* History of other autoimmune or inflammatory skin disease
* Current immunodeficiency state (cancer, HIV, others)
* Current immunodeficiency state (cancer, HIV, Other)
* Concern for inability of the patient to comply with study procedure, and or follow up (alcohol or drug abuse)
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
NYU Langone Health
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jose Scher, MD
Role: PRINCIPAL_INVESTIGATOR
NYU Langone Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
New York University School of Medicine
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
17-00748
Identifier Type: -
Identifier Source: org_study_id